SightScore™ Family

About Seonix Bio

Seonix Bio is an early-stage diagnostics company commercializing a polygenic risk score (PRS) test called SightScore™ for predicting genetic risk of glaucoma and age-related macular degeneration (AMD). The company leverages extensive genetic research published in leading journals to provide a clinically relevant tool intended to guide monitoring and management decisions in ophthalmology. Currently available in the US, Australia, and New Zealand as a laboratory-developed test (LDT), Seonix targets both clinical use and research collaborations while navigating the pre-FDA approval regulatory pathway.

Therapeutic Areas